This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

开始日期2029-03-01

申办/合作机构

Womack Army Medical Center

[+1]

CTIS2024-518007-22-00

/ Recruiting临床3期

A Phase III Randomised, Open Label Trial of an Intradermal or Subcutaneous booster dose of MVA-BN Vaccine to Investigate MPXV Immunogenicity and Safety for Protection Against Mpox in an Intradermally or Subcutaneously Primary Vaccinated Population – an adaptive protocol and a Non-Randomised Trial of a Subcutaneous Booster Dose for Subcutaneously Primary Vaccinated

开始日期2025-12-05

申办/合作机构-

NCT07199569

/ Active, not recruiting临床2期

A Randomized, Double-blind, Phase 2b Comparability Trial in Adults 18 to 49 Years of Age to Assess Immunogenicity, Safety, and Reactogenicity of the MVA-BN Vaccine Manufactured in Different Production Cells

Randomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults

开始日期2025-10-27

申办/合作机构

Bavarian Nordic A/S

[+1]

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的临床结果

登录后查看更多信息

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的转化医学

登录后查看更多信息

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的专利（医药）

登录后查看更多信息

189

项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的文献（医药）

2026-08-01·VACCINE

Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies

Article

作者: Tshilumba, Solange Milolo ; Muteba, Dominique ; Kimbulu, Primo ; Muhindo-Mavoko, Hypolite ; Van Geertruyden, Jean-Pierre ; Mitashi, Felly ; Lemey, Gwen ; Azoum, Mahmoud Abu ; Kasereka, Gustave ; Jordan, Elke ; Salloum, Maha ; Bisumba, Aurelie ; Mitashi, Patrick ; Bikioli, Freddy ; Matuvanga, Trésor Zola ; Larivière, Ynke ; Ruiz, Paulina Morales ; Van Damme, Pierre ; Maketa, Vivi

INTRODUCTION:

This article describes the protocol of the PregInPoxVac vaccine trial, evaluating the safety and immunogenicity of two MVA-BN vaccination regimens (full-dose and half- dose) administered subcutaneously with a 28-day interval in infants aged 4 to <24 months old. Non-inferiority of the full dose and half dose regimens will be compared to adults receiving a full dose regimen as part of the POX-MVA-045 study (ClinicalTrials.govIdentifier:NCT06549530). The PregInPoxVac study is being conducted in Boende, Tshuapa Province, Democratic Republic of the Congo (DRC), a mpox-endemic area; the POX-MVA-045 study is being conducted in Kinshasa, DRC, and Entebbe, Uganda. This is a randomized, double-blind, phase 3 trial assessing two dosing regimens in infants, with immunogenicity and safety compared to a predefined adult reference dataset.

METHODS:

This is a phase 3, randomized, double-blind vaccine trial. A total of 344 healthy children aged 4 to <24 months will be enrolled at the Boende General Referral Hospital in the DRC. Participants will be randomized in a 1:1 ratio to receive either two full doses (0.5 mL) or two half doses (0.25 mL) of the MVA-BN® vaccine, administered subcutaneously 28 days apart. The primary objective is to evaluate the immunogenicity and safety of the paediatric vaccination regimen compared to the reference adult regimen, as defined in the POX-MVA-045 vaccine trial. Immunogenicity will be assessed through a hierarchical non-inferiority analysis of neutralizing antibody responses comparing full-dose and half-dose regimens in infants with the full-dose adult reference cohort. As a secondary analysis, the immunogenicity and safety observed in full dose infants will be compared to half dose infants. Additionally, total binding antibodies against vaccinia will also be compared between infants and adults as a secondary objective. Solicited adverse events (AEs) will be recorded for 7 days following each injection or until resolution of the event. Unsolicited AEs will be recorded for 28 days following each injection or until resolution of the event. Medically attended AEs (MAAEs), AEs of special interest (AESIs), serious AEs (SAEs) will be recorded from signing of the informed consent through 12 months after the second dose. Participant enrolment was conducted between 29 May and 30 October 2025.

ETHICS AND DISSEMINATION:

The protocol was approved by the Antwerp University Hospital Committee for Medical Ethics (Approval No. 2025-7480), the National Health Ethics Committee of the DRC Ministry of Health (CNES) (Approval No. 641/CNES/BN/PMMF/2025) and by the Congolese Pharmaceutical Regulatory Authority (ACOREP:Approval No. 556/ACRP/DG/CAB/D15/2025). The trial has been registered on ClinicalTrials.gov (Identifier: NCT06844487).Written informed consent will be obtained from all parents or legal guardians prior to any study-related procedures being performed. The results will be published in peer-reviewed scientific journals and presented at national and international conferences.

2026-07-01·DRUG SAFETY

Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness

Review

作者: Brizuela, Martin ; Castellana, Noelia ; Xiong, Xu ; Ciapponi, Agustín ; Comande, Daniel ; Stegelmann, Katharina ; Munoz, Flor M ; Mazzoni, Agustina ; Buekens, Pierre ; Salva, Florencia ; Couto, Esteban ; Caravario, Julieta ; Bardach, Ariel ; Sambade, Juan M ; Stergachis, Andy ; Ballivian, Jamile ; Berrueta, Mabel ; Parker, Edward

BACKGROUND:

Mpox is a re-emerging zoonotic infection caused by an Orthopoxvirus closely related to smallpox. The 2022-23 global outbreak prompted rapid use of vaccinia-based vaccines, historically developed for smallpox and those of the latest generation used for mpox prevention. Assessing their safety and effectiveness in pregnant persons and children is critical to guide policies protecting populations at an elevated risk of severe illness.

OBJECTIVE:

This study assessed the safety and effectiveness of mpox and historical smallpox vaccines, administered during pregnancy and childhood.

METHODS:

We conducted a living systematic review and meta-analysis (PROSPERO CRD42024591322/CRD42024586205) following Cochrane, World Health Organization, and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) standards. We searched biweekly across major databases, trial registries, preprints, and gray literature (inception to September 2025) for studies evaluating the safety and effectiveness of vaccinia-based smallpox vaccines, including historical (first- and second-generation) and modern (third-generation) vaccines, in maternal and pediatric populations. Reviewers independently conducted study selection, data extraction, and risk-of-bias assessment. Meta-analyses employed random-effects models, and results are presented through an interactive dashboard and a living platform.

RESULTS:

We included 27 clinical studies (1949-2025), involving 1,406,771 children/adolescents (eight studies) and 11,482 pregnant persons (19 studies). Most maternal data came from first-generation vaccines (Lister, Finnish, Dryvax, APSV). These vaccines were not associated with an increased risk of spontaneous abortion (risk ratio [RR] 1.02, 95% confidence interval [CI] 0.70-1.48), stillbirth (RR 1.02, 95% CI 0.70-1.48), or preterm birth (RR 1.08, 95% CI 0.78-1.50), but were linked to a higher risk of congenital anomalies (RR 1.25, 95% CI 1.01-1.54). Fifty-two fetal vaccinia cases were reported globally up to 1978, with none since. Evidence on second- (ACAM2000) and third-generation (MVA-BN) non-replicating vaccines remains limited. In children, serious adverse events were rare, and MVA-BN caused only mild self-limiting reactions. No study assessed vaccine effectiveness in pregnant persons, while limited pediatric data suggested possible protection after post-exposure prophylaxis.

CONCLUSIONS:

Vaccinia-based vaccines appear generally safe in pregnancy and children. However, evidence on the safety and effectiveness of third-generation mpox vaccines is still scarce. High-quality prospective studies and strengthened pharmacovigilance are urgently needed to inform policy and clinical decision making.

2026-06-01·LANCET INFECTIOUS DISEASES

Safety of MVA-BN vaccine in health-care personnel in DR Congo: a prospective cohort study

Article

作者: Monroe, Benjamin ; Petersen, Brett ; Minhaj, Faisal S ; McCollum, Andrea M ; Mandra, Anna ; Joseph, Taina ; Kokola, Gaston ; Kabamba, Joelle ; Yu, Yon ; Kennedy, Jordan L ; Kasongo, Dorah ; Shongo Lushima, Robert ; Townsend, Michael B ; Rao, Agam K ; Satheshkumar, Panayampalli S ; Nguete, Béatrice U ; Likafi, Toutou ; Yu, Patricia A ; Kaba, Didine ; Tran, Stephanie ; Person, Marissa K ; Hughes, Christine M ; Reynolds, Mary G

BACKGROUND:

Modified vaccinia Ankara-Bavarian Nordic (MVA-BN) is a third-generation, replication-deficient, smallpox and mpox vaccine that is prepared in liquid and lyophilised formulations. DR Congo reports the highest number of mpox cases annually. Safety data on MVA-BN are available from high-income countries, but comprehensive safety evaluations of MVA-BN are limited in the African continent.

METHODS:

From Feb 23 to Aug 29, 2017, and from Aug 15 to Sept 17, 2019, 1600 adult (aged 18 years and older) health-care personnel (eg, physicians, nurses, and technicians) at risk for mpox in the Tshuapa province and in Kinshasa were enrolled in an investigational prospective cohort study to evaluate safety of the two-dose MVA-BN vaccine series. Participants were excluded if they were pregnant, acutely ill, involved in another research study or had vaccine administration in the past 28 days, or had conditions that could have put the participant at an unacceptable risk. 1000 (62·5%) participants were administered the liquid formulation and 600 (37·5%) participants were administered the reconstituted lyophilised formulation. Vaccine doses were given on study days 0 and 28 and participants followed up at specified timepoints for up to 2 years for serological monitoring (14, 28, 42, 180, 365, 545, and 730 days). Participants were evaluated for immediate vaccine reactions, given adverse event diaries to document specific adverse events for 7 days following vaccine administration, and asked about potential adverse events at later timepoints up to the 2-year mark. The primary outcome was to assess the safety of MVA-BN for up to 2 years across formulations in a population at increased risk of mpox. This study is registered with ClinicalTrials.gov (NCT02977715).

FINDINGS:

There was no significant difference in the risk of an adverse event between the liquid formulation (488 [49·0%] of 995 participants) and lyophilised formulation (315 [53·7%] of 586 participants; adjusted risk ratio [aRR] 1·08 [95% CI 0·98-1·19]) within 7 days after vaccination. Within 7 days of vaccine administration, participants had similar proportions of local injection-site reactions between the liquid (356 [35·7%] of 995 participants) and lyophilised (213 [36·3%] of 586 participants) formulations, but those who received the lyophilised formulation had a higher risk for systemic symptoms than those who received the liquid formulation (aRR 1·20 [95% CI 1·05-1·37]). 18 serious adverse events, including 17 deaths and one stillbirth, occurred within the 2-year study period; safety monitors (two board-certified physicians: one in the USA and one in DR Congo) deemed none of the events were causally associated with vaccine administration. 14 pregnancies occurred within 1 month of vaccination and 13 resulted in the birth of healthy infants.

INTERPRETATION:

This study adds to the growing body of literature on the safety of MVA-BN in different populations. Although limited by incomplete grading of specific adverse events, low numbers of pregnant participants, and differences in health-care access and infrastructure, the data from this cohort in DR Congo do show good safety outcomes for up to 2 years with both liquid and lyophilised vaccine formulations. Because MVA-BN vaccination campaigns are crucial to clade I and clade II mpox outbreak responses, the data from this study supporting safety of MVA-BN in this population are key to build vaccine confidence.

FUNDING:

US Centers for Disease Control and Prevention and the US Biomedical Advanced Research and Development Authority.

TRANSLATION:

For the French translation of the abstract see Supplementary Materials section.

417

项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的新闻（医药）

2026-08-08

·肖生客

8月8日创新药全球见闻

1️⃣ CMS为大麻产品开500美元医保通道引争议美国CMS创新中心4月启动"物质获取受益人激励"，让参与ACO REACH等模型的组织在医生指导下，为受益人大麻衍生品提供每人每年最高500美元。CMS管理员奥兹博士一边要求正规药企走FDA审批，一边为未经批准产品开口子，被大麻素药企MMJ公开质疑双重标准。（ACCESS Newswire/CMS） 2️⃣ 武田嗜睡症药Orzeyful获FDA批准 FDA批准武田Orzeyful（oveporexton），为首款治疗1型发作性睡病全谱症状的药物，覆盖白天嗜睡与猝倒。这是增强食欲素机制的首个获批药，中美两地均已获批，睡眠神经科学赛道开闸。（Managed Healthcare Executive） 3️⃣ aTyr Pharma发布二季度业绩与研发规划 aTyr Pharma公布2026年二季度业绩，聚焦免疫调节疗法管线关键数据更新，同步披露资源分配策略以支持后续临床推进与潜在合作，生物制药投入持续加码。（GlobeNewswire） 4️⃣ 小公司挑战Vertex囊性纤维化帝国一家小型生物技术公司试图挑战Vertex在囊性纤维化治疗的主导地位，希望以创新机制或更优疗效打破格局。能否在临床数据、审批或商业化上找到突破口，将决定这场竞争走向。（The Motley Fool） 5️⃣ X连锁视网膜色素变性市场受关注 XLRP主要影响男性，导致进行性视野缩小和视力丧失。随着基因疗法和视网膜植入等新技术推进，多家机构加速临床研究，有望填补这一遗传性眼科疾病的治疗空白。（Future Market Insights） 6️⃣ 中国批准TransThera的Yochanra 国家药监局批准TransThera的Yochanra药物上市，为相关患者提供新治疗选择。中国创新药审批持续提速，企业产品获批进一步丰富国内治疗手段。（The Pharma Letter） 7️⃣ 礼来9900万美元押注Same Biotech 小野资助纤维化研究礼来斥资9900万美元投资Same Biotech拓展生物技术布局，日本小野制药资助纤维化研究。两项投资均聚焦未满足医疗需求，体现跨国药企对前沿方向的持续关注。（Tech Times） 8️⃣ FDA批准利洁时新型Mucinex感冒流感药 FDA批准利洁时新型Mucinex感冒流感药物上市，拓展其在非处方呼吸道药物领域的产品线，为消费者提供更多缓解感冒流感症状的选择。（NJBIZ） 9️⃣ 辉瑞战略官鲍姆：中国生物技术接近前沿将放缓辉瑞首席战略官安德鲁·鲍姆在MIT表示，中国生物技术快速进步将在接近研发前沿时放缓，形成"寒蝉效应"。但2024年中国临床试验数首超美国、2025年五千万美元级授权中国占42%——"放缓论"面临数据反证。（Endpoints News） 🔟 礼来FDA批准前向部分患者提供新减肥药礼来在FDA正式批准前向部分患者提供新型减肥药物，让特定人群提前获得治疗机会，反映其在减肥药市场竞争中的积极布局，或对现有市场格局产生影响。（LiveNOW from FOX） 🧬 CGT+mRNA+罕见病专题 BioMarin三期失败削减2.7亿美元资产 BioMarin因一项三期临床试验未达主要终点，决定削减价值2.7亿美元的资产，并停产罕见病药物BMN401。研发管线优先级调整，短期财务与长期战略均受影响。（Fierce Biotech） CSL与Arcturus终止mRNA合作 CSL与Arcturus终止mRNA合作协议，CSL支付1200万美元终止费用；Bavarian Nordic的Imvanex疫苗获欧盟批准可用于2-11岁儿童。mRNA赛道合作调整，疫苗适应症持续扩展。（Endpoints News） #创新药出海 #基因治疗 #ADC #CGT #GLP1 #生物医药

2026-08-07

·BioSpace

Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years

MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus Approval further strengthens MVA-BN’s position in supporting global public health preparedness COPENHAGEN, Denmark, August 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the recent Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the approval of a type II variation for IMVANEX ® (MVA-BN) smallpox and mpox vaccine, extending the current marketing authorization to include children 2 to less than 12 years of age. The approval is based on data from a Phase 2 clinical study ( NCT06549530 ) involving 227 children aged 2 to <12 years and 224 adults, demonstrating non-inferior immune responses and a similar safety pro children compared to adults following vaccination with two standard doses of MVA-BN. The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI). With this approval, MVA-BN is now authorized in the European Union for use in individuals aged 2 years and older, marking a significant expansion of access to a non-replicating vaccine designed to help protect vulnerable populations against mpox, smallpox and disease caused by vaccinia virus. Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, said : “The European Commission's approval of MVA-BN for children aged 2 to less than 12 years represents an important advancement in our efforts to broaden access to protection against mpox and smallpox. Children have carried a disproportionate burden during recent mpox outbreaks, particularly in parts of Africa, underscoring the importance of making safe and effective vaccines available to this vulnerable population. We are grateful to the study participants, investigators, CEPI and our partners whose collaboration helped generate the data supporting this approval.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The approval adds to the growing body of clinical evidence supporting the use of MVA-BN across age groups and further strengthens Bavarian Nordic's commitment to supporting global public health preparedness and outbreak response. About the mpox and smallpox vaccine MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore, Mexico (marketed as JYNNEOS ® ), Canada (marketed as IMVAMUNE ® ), the EU/EEA European Economic Area and United Kingdom (marketed as IMVANEX ® ). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population (from 2 years old) in individuals considered at risk for smallpox or mpox infection. About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel: +45 33 26 83 83 Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 Attachment Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years

上市批准临床2期疫苗加速审批

2026-08-06

·Pharmaindustrial

EC Approves Bavarian Nordic's Mpox Vaccine for Children

Bavarian Nordic recently announced that the European Commission (EC) has adopted the recent Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the approval of a type 2 variation for IMVANEX (MVA-BN) smallpox and mpox vaccine, extending the current Marketing Authorisation (MA) to include children 2 to less than 12 years of age. The approval is based on data from a phase 2 clinical study (NCT06549530) involving 227 children aged 2 to <12 years and 224 adults, demonstrating non-inferior immune responses and a similar safety profile in children compared to adults following vaccination with 2 standard doses of MVA-BN. The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI). With this approval, MVA-BN is now authorised in the European Union (EU) for use in individuals aged 2 years and older, marking a significant expansion of access to a non-replicating vaccine designed to help protect vulnerable populations against mpox, smallpox and disease caused by vaccinia virus. Paul Chaplin, President and Chief Executive Officer (CEO), Bavarian Nordic, said, “The European Commission's approval of MVA-BN for children aged 2 to less than 12 years represents an important advancement in our efforts to broaden access to protection against mpox and smallpox. Children have carried a disproportionate burden during recent mpox outbreaks, particularly in parts of Africa, underscoring the importance of making safe and effective vaccines available to this vulnerable population. We are grateful to the study participants, investigators, CEPI and our partners whose collaboration helped generate the data supporting this approval.” The approval adds to the growing body of clinical evidence supporting the use of MVA-BN across age groups and further strengthens Bavarian Nordic's commitment to supporting global public health preparedness and outbreak response.

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	天花和猴痘活疫苗(Bavarian Nordic A/S)	J07BX	DB15483

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
猴痘	欧盟	Bavarian Nordic A/S	2013-07-31
猴痘	冰岛	Bavarian Nordic A/S	2013-07-31
猴痘	列支敦士登	Bavarian Nordic A/S	2013-07-31
猴痘	挪威	Bavarian Nordic A/S	2013-07-31
天花	欧盟	Bavarian Nordic A/S	2013-07-31
天花	冰岛	Bavarian Nordic A/S	2013-07-31
天花	列支敦士登	Bavarian Nordic A/S	2013-07-31
天花	挪威	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	欧盟	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	冰岛	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	列支敦士登	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	挪威	Bavarian Nordic A/S	2013-07-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05740982 (CTgov)	临床2期	猴痘	450	MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) (Adolescents)	膚餘獵構願獵製繭壓製(鬱餘顧齋憲鹹願製獵繭) = 願網憲鏇廠蓋鬱齋網膚繭鑰鹹夢壓廠艱築築積 (鹽鹹艱觸蓋鬱蓋獵積範, 願選構顧觸艱製夢醖築 ~ 願鹽窪遞餘憲艱遞鹹簾) 更多	-	2026-03-27
				MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) (Adults (Stage 2))	膚餘獵構願獵製繭壓製(鬱餘顧齋憲鹹願製獵繭) = 淵範鹽憲鬱鹽鑰齋襯蓋繭鑰鹹夢壓廠艱築築積 (鹽鹹艱觸蓋鬱蓋獵積範, 網艱鏇鹹構艱範壓鹽憲 ~ 憲築遞衊蓋淵鹹鏇廠鹽) 更多
NCT05734508 (CTgov)	临床4期	猴痘	500	MVA-BN Mpox Vaccine	糧鏇餘選繭簾築窪窪壓 = 顧夢鹹糧鑰艱觸積壓蓋淵繭淵襯簾簾鬱網獵製 (夢顧艱鑰蓋鹹憲襯襯網, 餘膚壓繭顧夢廠醖構憲 ~ 艱簾繭遞顧構構窪憲膚) 更多	-	2026-02-12
NCT05512949 (NEWS) 人工标引	临床2期	猴痘	229	MVA-BN (aged between 12 and 17 years)	網獵遞築蓋網蓋齋觸網(網壓壓鹽鹹願積襯製鹹) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. 淵憲鹹顧積淵簾製齋壓 (獵窪繭夢願網蓋淵鹹餘 ) 更多	积极	2024-10-17
Literature 人工标引	N/A	猴痘	45	MVA-BN 2 doses	繭憲壓糧製廠獵膚鬱築(選鬱淵鹹醖壓襯壓築選) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months 鹽淵壓觸鹽襯獵餘齋鏇 (鏇衊艱艱鹽窪鏇餘築觸 )	不佳	2024-10-03
				MVA-BN 1 doses
NCT05740982 (NEWS) 人工标引	临床2期	埃博拉病毒性疾病	526	IMVANEX (adolescents 12-17 years of age)	餘鬱餘積淵鏇窪範構鹽(積艱膚鬱齋鏇醖鑰齋淵) = a similar safety profile between both age groups 淵範窪獵餘鏇衊顧範鬱 (觸壓築窪齋獵蓋築夢艱 ) 更多	积极	2024-09-19
				IMVANEX (adults aged 18 years and older)
NCT05512949 (CTgov)	临床2期	猴痘	229	MVA-BN (2 x 10^7 ID MVA-BN)	繭範鏇構簾窪顧醖艱遞(窪餘構鏇膚襯廠襯顧願) = 醖鏇顧築積願鹽願鹽構衊獵艱選淵選鹹積鹹鏇 (淵鹽鹽鑰鹹糧衊餘顧鏇, 蓋窪廠醖鹹鏇鏇膚艱壓 ~ 衊衊衊憲廠襯糧鏇鬱選) 更多	-	2024-01-09
				MVA-BN (1 x 10^7 ID MVA-BN)	繭範鏇構簾窪顧醖艱遞(窪餘構鏇膚襯廠襯顧願) = 製製壓簾簾鹽範鬱膚製衊獵艱選淵選鹹積鹹鏇 (淵鹽鹽鑰鹹糧衊餘顧鏇, 鏇繭壓壓廠廠廠簾襯鏇 ~ 範顧壓繭積繭衊衊鬱夢) 更多
NCT03699124 (Pubmed) 人工标引	临床3期	-	1,129	MVA-BN	艱鏇簾築鹽觸蓋襯獵淵(積範觸簾襯醖襯觸網壓) = 窪簾願鹹蓋糧艱廠範憲鬱艱簾簾淵壓糧願醖餘 (鹽衊膚憲鏇鹹鹽願鏇齋 ) 更多	积极	2022-11-29
NCT03699124 (CTgov)	临床3期	天花	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	鏇鏇齋襯膚衊醖醖鹹簾(糧願鹽願網鹹鬱鑰願窪) = 壓觸廠鑰鹽顧繭顧蓋鹽鹹艱選鬱築鑰廠蓋艱淵 (壓廠淵顧餘構構繭襯壓, 願鬱餘鹹艱築鏇鑰壓願 ~ 窪願選衊構鬱繭艱憲憲) 更多	-	2021-05-27
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	鏇鏇齋襯膚衊醖醖鹹簾(糧願鹽願網鹹鬱鑰願窪) = 襯壓艱鏇顧簾衊衊壓廠鹹艱選鬱築鑰廠蓋艱淵 (壓廠淵顧餘構構繭襯壓, 觸壓繭壓鹹遞顧網選簾 ~ 淵餘繭鑰襯繭顧餘遞遞) 更多
NCT01668537 (CTgov)	临床2期	天花	651	LF (LF Formulation)	衊醖夢觸願糧願獵繭積(觸憲願膚選遞構遞築繭) = 觸鏇繭構獵醖簾糧膚簾醖願願範齋膚餘積選蓋 (顧鏇製網餘壓築鹽餘夢, 網淵繭餘築築襯鏇蓋鹽 ~ 鏇廠廠醖夢積艱選獵遞) 更多	-	2020-10-12
				MVA-BN (FD Formulation)	衊醖夢觸願糧願獵繭積(觸憲願膚選遞構遞築繭) = 艱壓淵願簾衊鬱顧製餘醖願願範齋膚餘積選蓋 (顧鏇製網餘壓築鹽餘夢, 獵鏇觸鹽遞憲選襯齋蓋 ~ 鏇衊廠艱鹹糧鬱鹽願齋) 更多
NCT03472014 (CTgov)	临床4期	-	22	MVA-BN	願襯艱艱簾蓋積衊積齋 = 淵艱衊壓鏇獵蓋艱襯顧艱獵憲遞衊廠築廠鹹糧 (製觸齋糧襯願蓋壓艱衊, 繭襯鬱蓋選襯簾夢衊蓋 ~ 襯糧夢觸蓋膚淵襯網獵) 更多	-	2020-08-19